Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$12.59 - $18.8 $166,188 - $248,160
-13,200 Closed
0 $0
Q1 2022

Feb 14, 2023

BUY
$12.02 - $16.69 $158,664 - $220,308
13,200 New
13,200 $215,000
Q1 2022

May 13, 2022

SELL
$12.02 - $16.69 $70,918 - $98,471
-5,900 Reduced 30.89%
13,200 $216,000
Q4 2021

Feb 14, 2022

SELL
$10.69 - $16.83 $47,036 - $74,051
-4,400 Reduced 18.72%
19,100 $312,000
Q3 2021

Nov 15, 2021

BUY
$11.5 - $14.86 $270,250 - $349,210
23,500 New
23,500 $300,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.